CHIEF MEDICAL OFFICER
Paul K. Audhya, MD, MBA is the Chief Medical Officer of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company focused on small molecule protease inhibitors for diseases with significant unmet need.[[1]](https://www.citybiz.co/article/52328/kalvista-pharmaceuticals-appoints-paul-k-audhya-md-mba-as-chief-medical-officer/)[[6]](https://www.kalvista.com/about/senior-management/) A corporate insider at KalVista, he brings over 20 years of clinical development and global medical affairs leadership experience across multiple therapeutic areas, including rare diseases.[[1]](https://www.citybiz.co/article/52328/kalvista-pharmaceuticals-appoints-paul-k-audhya-md-mba-as-chief-medical-officer/)[[3]](https://www.nasdaq.com/press-release/kalvista-pharmaceuticals-expands-senior-leadership-team-with-appointment-of-paul-k.)[[4]](https://www.occam-global.com/placements/occam-places-paul-audhya-as-cmo-of-kalvista) In this role, he oversees clinical strategy and development, as well as medical affairs activities that support the company’s pipeline and commercial planning.[[1]](https://www.citybiz.co/article/52328/kalvista-pharmaceuticals-appoints-paul-k-audhya-md-mba-as-chief-medical-officer/)[[6]](https://www.kalvista.com/about/senior-management/)
Before joining KalVista, Audhya served as Senior Vice President, Global Medical Affairs at Arena Pharmaceuticals, where he built and led all global medical affairs functions, including health economics and outcomes research and global patient advocacy.[[1]](https://www.citybiz.co/article/52328/kalvista-pharmaceuticals-appoints-paul-k-audhya-md-mba-as-chief-medical-officer/)[[3]](https://www.nasdaq.com/press-release/kalvista-pharmaceuticals-expands-senior-leadership-team-with-appointment-of-paul-k.) He previously held senior roles at Vertex Pharmaceuticals as Vice President, Global Strategy and Phase 4, Global Medical Affairs, leading global launch and lifecycle management for the cystic fibrosis portfolio, and at Hospira Inc. as Vice President, Medical Affairs, where he helped introduce global biosimilar strategies and supported the first monoclonal biosimilar launch in the EU.[[1]](https://www.citybiz.co/article/52328/kalvista-pharmaceuticals-appoints-paul-k-audhya-md-mba-as-chief-medical-officer/)[[3]](https://www.nasdaq.com/press-release/kalvista-pharmaceuticals-expands-senior-leadership-team-with-appointment-of-paul-k.) Earlier in his career, he held positions of increasing responsibility at Reata Pharmaceuticals, Abbott Laboratories, Amgen, Bristol Myers Squibb, and Janssen.[[1]](https://www.citybiz.co/article/52328/kalvista-pharmaceuticals-appoints-paul-k-audhya-md-mba-as-chief-medical-officer/) Audhya earned both his BA and MD from New York University, completed an Internal Medicine residency at the University of Medicine and Dentistry of New Jersey, and obtained his MBA from Pepperdine University.[[1]](https://www.citybiz.co/article/52328/kalvista-pharmaceuticals-appoints-paul-k-audhya-md-mba-as-chief-medical-officer/)
View full insider profile →
Discussion